Article
A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells.
Molecular cancer therapeutics - 1 May 2018
Inoue Akira, Mizushima Tsunekazu, Wu Xin, Okuzaki Daisuke, Kambara Nanami, Ishikawa Sho, Wang Jiaqi, Qian Yamin, Hirose Haruka, Yokoyama Yuhki, Ikeshima Ryo, Hiraki Masayuki, Miyoshi Norikatsu, Takahashi Hidekazu, Haraguchi Naotsugu, Hata Taishi, Matsuda Chu, Doki Yuichiro, Mori Masaki, Yamamoto Hirofumi
Abstract excerpt
We previously demonstrated that miR-29b-3p is a hopeful miRNA-based therapy against colorectal cancer. In this study, we aimed to clarify a value of miR-29b-1-5p as a next-generation treatment, especially for KRAS-mutant colorectal cancer. RT-PCR assay showed that the expression of miR-29b-3p was high, and its partner strand, miR-29b-1-5p, level was only negligible in clinical colorectal cancer samples....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.